A couple struggling to access to a vital cancer treatment say they are are "extremely stressed" by the uncertainty in its ...

Dublin, Oct. 02, 2023 (GLOBE NEWSWIRE) -- The "Enzyme Replacement Therapy Global Market Report 2023" report has been added to ResearchAndMarkets.com's offering. The global enzyme replacement therapy ...

New York, Oct. 08, 2021 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Enzyme Replacement Therapy Market Research Report by Therapeutic Condition, by Route of Administration ...

Researchers have given the gene therapy made at UManchester to two out of five planned patients in a Phase I/II trial, and ...

market Study Report has added a new report on Enzyme Replacement Therapy market with respect to the pivotal drivers influencing the revenue graph of this business sphere. The current trends of Enzyme ...

The global enzyme replacement therapy (ERT) targeting Pompe disease market is projected to attain a value of $350 million in 2025, growing at a compound annual growth rate (CAGR) of 12% between 2025 ...

OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) today announced that the U.S. Food and Drug Administration (FDA) has approved ADZYNMA (ADAMTS13, recombinant-krhn) for the ...

Please provide your email address to receive an email when new articles are posted on . Researchers analyzed 19 children with Pompe disease seen at a Texas-based children’s hospital.

Takeda’s recombinant ADAMTS13 (rADAMTS13) has been recommended by the European Medicines Agency’s human medicines committee to treat ADAMTS13 deficiency in children and adults with congenital ...

Dublin, Feb. 07, 2025 (GLOBE NEWSWIRE) -- The "Enzyme Replacement Therapy Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F" report has been added to ...

FDA reports rare neutralizing antibodies, including a pediatric death, in patients treated with Takeda's Adzynma for congenital TTP.